US Patent 7227008 13-transmembrane protein expressed in prostate cancer
Patent 7227008 was granted and assigned to Agensys on June, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Arthur B. Raitano0
Daniel E. H. Afar0
Douglas C. Saffran0
Kahan Leong0
Rene S. Hubert0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+334 characters)
Article
Patent abstract
A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07227008 13-transmembrane protein expressed in prostate cancer US Patent 7227008 13-transmembrane protein expressed in prostate cancer
Infobox
Patent Number
072270080
Patent Number
72270080
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072270080
Date of Patent
June 5, 2007
0Patent Application Number
108076350
Date Filed
March 23, 2004
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07227008 13-transmembrane protein expressed in prostate cancer
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07227008
Date of patent
June 5, 2007
Patent application number
10807635
Date Filed
March 23, 2004
Patent primary examiner
Find more entities like US Patent 7227008 13-transmembrane protein expressed in prostate cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.